Floatz logo

mk-2206

Juvenile Myelomonocytic Leukemia

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

29 Active assets in the Juvenile Myelomonocytic Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Masonic Cancer Center, University of Minnesota
Phase 4BBB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 4BBB
Thiotepa
St. Jude Children's Research Hospital
Phase 3BBB
Fludarabine
Children's Oncology Group
Phase 3BB
FILGRASTIM
Masonic Cancer Center, University of Minnesota
Phase 3BB

View all 46 →

Same molecule, other indications

mk-2206 is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
diffuse large B-cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
prostate cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →